DOCSLIB.ORG

WO 2018/077926 Al 03 May 2018 (03.05.2018) WIPO I PCT

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2018/077926 Al 03 May 2018 (03.05.2018) WIPO I PCT (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property llllllllllllllllllllllllllllllll^ Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/077926 Al 03 May 2018 (03.05.2018) WIPO I PCT (51) International Patent Classification: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, C07K16/28 (2006.01) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: (84) Designated States (unless otherwise indicated, for every PCT/EP2017/077261 kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (22) International Filing Date: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 25 October 2017 (25.10.2017) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (25) Filing Language: English EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (26) Publication Language: English TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (30) Priority Data: KM, ML, MR, NE, SN, TD, TG). 16306392.8 25 October 2016 (25.10.2016) EP Published: (71) Applicants: INSERM (INSTITUT NATIONAL DE — with international search report (Art. 21(3)) LA SANTE ET DE LA RECHERCHE MEDICALE) — with sequence listing part of description (Rule 5.2(a)) [FR/FR]; 101, rue de Tolbiac, 75013 Paris (FR). UNIVERSITE PARIS DIDEROT - PARIS 7 [FR/FR]; 5, rue Thomas Mann, 75013 Paris (FR). UNIVERSITE DE MONTPELLIER [FR/FR]; 163, rue Auguste Broussonnet, 34090 Montpellier (FR). INSTITUT JEAN GODINOT = [FR/FR]; 1 RUE DU GENERAL KOENIG, 51100 REIMS (FR). INSTITUT REGIONAL DU CANCER DE __ MONTPELLIER [FR/FR]; 208, Rue Des Apothicaires - == Parc Euromedecine, 34298 Montpellier (FR). (72) Inventors: BENSUSSAN, Armand; U976 - Hopital Saint Louis, 1 Avenue Claude Vellefaux - Pavilion Bazin, 75010 Paris (FR). ROBERT, Bruno; U1194 / ~~ IRCM, 208, rue des Apothicaires, 34298 MONTPEL­ LIER (FR). MARTINEAU, Pierre; U1194 / IRCM, 208, rue des Apothicaires, 34298 MONTPELLIER Cedex 5 (FR). CHENTOUF, Myriam; U1194 / IRCM, 208 rue des Apothicaires, 34298 MONTPELLIER Cedex 5 (FR). MARIE-CARDINE, Anne; HOPITAL SAINT LOUIS - ΞΞ INSERM U976 1 avenue Claude Vellefaux, 75010 PARIS (FR)· GUSTINIANI, Jerome; EA7319 / Universite de Reims Champagne-Ardenne, 9 Boulevard de la Paix, 51100 ΞΞ REIMS (FR). ~~ (74) Agent: COLLIN, Matthieu; Inserm Transfert, 7 rue Watt, 75013 PARIS (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, Al MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: MONOCLONAL ANTIBODIES BINDING TO THE CD 160 TRANSMEMBRANE ISOFORM (57) Abstract: The present invention relates to monoclonal antibodies that bind to the CD160-TM isoform. The inventors developed new monoclonal antibodies which bind to the CD160-TM isoform but dot not bind to the CD 160 GPI-anchored isoform not to the 2018/077926 CD 160 soluble isoform.In particular, the antibodies of the present invention are suitable for amplifying NK cell activation and therefore cytotoxic functions NK cells. WO WO 2018/077926 PCT/EP2017/077261 MONOCLONAL ANTIBODIES BINDING TO THE CD160 TRANSMEMBRANE ISOFORM 5 FIELD OF THE INVENTION: The present invention relates to antibodies (preferably monoclonal antibodies) binding to the CD160-TM isoform. BACKGROUND OF THE INVENTION: 10 CD 160 has been initially identified as a GPI-anchored (CD160-GPI) MHC-class I activating receptor mainly expressed on peripheral blood NK cells. It was additionally reported the identification of a CDf60 transmembrane isoform (CDf60-TM) resulting from the alternative splicing of CD 160 gene. It was established that CD160-TM surface expression is highly restricted to NK cells and is activation-dependent (Giustiniani J et al. J Immunol. 2009 15 Jan 1; 182(1):63-71). Indeed, CD160-TM is only expressed by activated NK cells, whereas CD160-GPI is expressed by NK cells (activated or not) and by different subsets of T cells. In addition, it was provided evidences that CD160-TM represent a novel activating receptor, as assessed by the increased CD 107a NK cell surface mobilization observed upon its engagement (Giustiniani J et al. 2009). 20 Accordingly, antibodies that bind to the CD160-TM isoform without binding to the CD 160 GPI-anchored isoform nor to the CD 160 soluble isoform that may result from the proteolytic cleavage of the CD 160-GPI isoform can thus be suitable, for example for amplifying NK cell activation and therefore effector functions of NK cells (cytotoxicity, cytokine secretion etc.) or for inducing depletion of CD160-TM expressing cells (in particular activated NK cells) 25 in vivo. In particular, using an antibody capable of binding to the CD160-TM isoform but not to the CD 160-GPI iso form will avoid any systemic toxicity such as cytokine storm risk. W02008/009711 describes antibody CL1-R2, an IgGl capable of binding CD160-GPI. Giustiniani J. et al. (Curr Mol Med. 2012 Feb;12(2):188-98.) describes a monoclonal antibody that binds to the CD160-TM isoform. However, this antibody also binds the soluble 30 isoform of CD 160. W02008/155363 describes the production of polyclonal antibodies directed to CD 160- TM but not binding to the CD 160-GPI isoform. These antibodies were obtained by immunizing rabbits with a peptide (peptide 2) comprising amino acids 144-158 of CD160-TM (KQRQHLEFSHNNEGTL, SEQ ID NO: 32). 1 WO 2018/077926 PCT/EP2017/077261 In the present invention, the Inventors developed a novel antibody binding to the CD160-TM isoform, but not to the CD160-GPI or to the soluble CD 160 isoforms. SUMMARY OF THE INVENTION: 5 The present invention relates to human antibodies (preferably monoclonal antibodies) binding to the CD160-TM iso form. In particular, the present invention is defined by the claims. In particular, the present invention relates to a monoclonal antibody which binds to the extracellular domain of the CD160-TM isoform, wherein said antibody does not bind to the GPI-anchored isoform nor to the CD 160 soluble isoform, and wherein the epitope of said 10 monoclonal antibody comprises at least one amino acid residue from amino acid residues 175 to 189 of SEQ ID NO: 1. In one embodiment, said epitope further comprises at least one amino acid residue from amino acid residues 62 to 85 of SEQ ID NO: 1. In one embodiment, the monoclonal antibody of the invention is a chimeric antibody, a 15 humanized antibody or a human antibody. In one embodiment, the monoclonal antibody of the invention comprises a light chain comprising at least one of the following CDR: i) the VL-CDR1 as set forth in SEQ ID NO: 6 wherein Xu is Y or S and X12 is G or Y, ii) the VL-CDR2 as set forth in SEQ ID NO: 7 and iii) the VL-CDR3 as set forth in SEQ ID NO: 8 wherein X3 is S or Y, and/or a heavy chain 20 comprising at least one of the following CDR i) the VH-CDR1 as set forth in SEQ ID NO: 9 wherein X3 is S or Y, ii) the VH-CDR2 as set forth in SEQ ID NO: 10 wherein Xi is Y or G and X10 is N or S and iii) the VH-CDR3 as set forth in SEQ ID NO: 11. In one embodiment, the monoclonal antibody of the invention comprises a light chain comprising the following CDR: i) the VL-CDR1 as set forth in SEQ ID NO: 6 wherein X11 is 25 Y or S and X12 is G or Y, ii) the VL-CDR2 as set forth in SEQ ID NO: 7 and iii) the VL-CDR3 as set forth in SEQ ID NO: 8 wherein X3 is S or Y, and a heavy chain comprising the following CDR i) the VH-CDR1 as set forth in SEQ ID NO: 9 wherein X3 is S or Y, ii) the VH-CDR2 as set forth in SEQ ID NO: 10 wherein Xi is Y or G and X10 is N or S and iii) the VH-CDR3 as set forth in SEQ ID NO: 11. 30 In one embodiment, the monoclonal antibody of the invention comprises a light chain comprising the following CDR: i) VL-CDR1: AGTSSDVGGYYGVS (SEQ ID NO: 20), ii) VL-CDR2: YDSYRPS (SEQ ID NO: 7) and iii) VL-CDR3: SSSTYYSTRV (SEQ ID NO: 24), and the heavy chain of the A12 antibody comprises the following CDR i) VH-CDR1: NYSMN 2 WO 2018/077926 PCT/EP2017/077261 (SEQ ID NO: 26), ii) VH-CDR2: YIYGSSRYISYADFVKG (SEQ ID NO: 29) and iii) VH- CDR3: GMDV (SEQ ID NO: 11). In one embodiment, the monoclonal antibody of the invention comprises a light chain comprising the following CDR: i) VL-CDR1: AGTSSDVGGYSYVS (SEQ ID NO: 23), ii) 5 VL-CDR2: YDSYRPS (SEQ ID NO: 7) and iii) VL-CDR3: SSYTYYSTRV (SEQ ID NO: 25), and the heavy chain of the A12 antibody comprises the following CDR i) VH-CDR1: NYYMN (SEQ ID NO: 27), ii) VH-CDR2: GIYGSSRYINYADFVKG (SEQ ID NO: 30) and iii) VH- CDR3: GMDV (SEQ ID NO: 11).
Load more

Recommended publications
  • Wo2015188839a2
    Downloaded from orbit.dtu.dk on: Oct 08, 2021 General detection and isolation of specific cells by binding of labeled molecules Pedersen, Henrik; Jakobsen, Søren; Hadrup, Sine Reker; Bentzen, Amalie Kai; Johansen, Kristoffer Haurum Publication date: 2015 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): Pedersen, H., Jakobsen, S., Hadrup, S. R., Bentzen, A. K., & Johansen, K. H. (2015). General detection and isolation of specific cells by binding of labeled molecules. (Patent No. WO2015188839). General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/188839
    [Show full text]
  • Human Antibodies That Bind CXCR4 and Uses Thereof CXCR4-Bindende Humane Antikörper Und Deren Verwendungen Anticorps Humains Liant Le CXCR4 Et Utilisations Associées
    (19) TZZ __T (11) EP 2 486 941 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 39/395 (2006.01) C07K 16/28 (2006.01) 15.03.2017 Bulletin 2017/11 (21) Application number: 12155398.6 (22) Date of filing: 01.10.2007 (54) Human antibodies that bind CXCR4 and uses thereof CXCR4-bindende humane Antikörper und deren Verwendungen Anticorps humains liant le CXCR4 et utilisations associées (84) Designated Contracting States: EP-A- 1 316 801 WO-A-2004/059285 AT BE BG CH CY CZ DE DK EE ES FI FR GB GR WO-A-2006/089141 US-A1- 2003 206 909 HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR • GHOBRIAL IRENE M ET AL: "The role of CXCR4 Designated Extension States: inhibitors as novel antiangiogenesis agents in RS cancer therapy", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, vol. 104, no. 11 (30) Priority: 02.10.2006 US 827851 P PART1, 1 November 2004 (2004-11-01), pages 365A-366A, XP002458710, ISSN: 0006-4971 (43) Date of publication of application: • ENDRES M J ET AL: "CD4-INDEPENDENT 15.08.2012 Bulletin 2012/33 INFECTION BY HIV-2 IS MEDIATED BY FUSIN/CXCR4", CELL, CELL PRESS, (62) Document number(s) of the earlier application(s) in CAMBRIDGE, NA, US, vol. 87, 15 November 1996 accordance with Art. 76 EPC: (1996-11-15), pages745-756, XP002920421, ISSN: 07867192.2 / 2 066 351 0092-8674 • BARIBAUD FREDERIC ET AL: "Antigenically (73) Proprietor: E.
    [Show full text]
  • WO 2018/098356 Al 31 May 2018 (31.05.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/098356 Al 31 May 2018 (31.05.2018) W !P O PCT (51) International Patent Classification: co, California 94124 (US). DUBRIDGE, Robert B.; 825 A61K 39/395 (2006.01) C07K 16/28 (2006.01) Holly Road, Belmont, California 94002 (US). LEMON, A61P 35/00 (2006.01) C07K 16/46 (2006.01) Bryan D.; 2493 Dell Avenue, Mountain View, California 94043 (US). AUSTIN, Richard J.; 1169 Guerrero Street, (21) International Application Number: San Francisco, California 941 10 (US). PCT/US20 17/063 126 (74) Agent: LIN, Clark Y.; WILSON SONSINI GOODRICH (22) International Filing Date: & ROSATI, 650 Page Mill Road, Palo Alto, California 22 November 201 7 (22. 11.201 7) 94304 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Langi English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (30) Priority Data: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/426,069 23 November 2016 (23. 11.2016) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/426,077 23 November 2016 (23. 11.2016) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (71) Applicant: HARPOON THERAPEUTICS, INC. KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, [US/US]; 4000 Shoreline Court, Suite 250, South San Fran MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, cisco, California 94080 (US).
    [Show full text]
  • Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
    Published OnlineFirst June 9, 2021; DOI: 10.1158/1078-0432.CCR-20-3770 CLINICAL CANCER RESEARCH | REVIEW Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy A C Belen Blanco1,2, Carmen Domínguez-Alonso1,2, and Luis Alvarez-Vallina1,2 ABSTRACT ◥ The recent advances in the field of immuno-oncology have here referred to as bispecific immunomodulatory antibodies, dramatically changed the therapeutic strategy against advanced have the potential to improve clinical efficacy and safety profile malignancies. Bispecific antibody-based immunotherapies have and are envisioned as a second wave of cancer immunotherapies. gained momentum in preclinical and clinical investigations Currently, there are more than 50 bispecific antibodies under following the regulatory approval of the T cell–redirecting clinical development for a range of indications, with promising antibody blinatumomab. In this review, we focus on emerging signs of therapeutic activity. We also discuss two approaches for and novel mechanisms of action of bispecific antibodies inter- in vivo secretion, direct gene delivery, and infusion of ex vivo acting with immune cells with at least one of their arms to gene-modified cells, which may become instrumental for the regulate the activity of the immune system by redirecting and/or clinical application of next-generation bispecific immunomod- reactivating effector cells toward tumor cells. These molecules, ulatory antibodies. Introduction of antibodies, such as linear gene fusions, domain-swapping strat- egies, and self-associating peptides and protein domains (Fig. 1B). The past decade has witnessed a number of cancer immunotherapy Multiple technology platforms are available for the design of bsAbs, breakthroughs, all of which involve the modulation of T cell–mediated allowing fine-tuning of binding valence, stoichiometry, size, flexi- immunity.
    [Show full text]
  • WO 2017/156178 Al 14 September 2017 (14.09.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/156178 Al 14 September 2017 (14.09.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/28 (2006.01) C07K 16/30 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 16/18 (2006.01) A61K 39/395 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2017/021435 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 8 March 2017 (08.03.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/305,092 8 March 2016 (08.03.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: MAVERICK THERAPEUTICS, INC. GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, [US/US]; 3260 B Bayshore Blvd., 1st Floor, Brisbane, CA TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 94005 (US).
    [Show full text]
  • Single-Round, Multiplexed Antibody Mimetic Design Through Mrna Display** C
    Angewandte Chemie DOI: 10.1002/anie.201207005 Ligand Design Single-Round, Multiplexed Antibody Mimetic Design through mRNA Display** C. Anders Olson, Jeff Nie, Jonathan Diep, Ibrahim Al-Shyoukh, Terry T. Takahashi, Laith Q. Al- Mawsawi, Jennifer M. Bolin, Angela L. Elwell, Scott Swanson, Ron Stewart, James A. Thomson, H. Tom Soh, Richard W. Roberts, and Ren Sun* There is a pressing need for new technologies to generate fold enrichment. Our results also demonstrate that highly robust, renewable recognition tools against the entire human functional binders (K 100 nm or better) are present with D proteome.[1] Hybridoma-based monoclonal antibodies,[2] the a frequency of > 1 in 109 in our library. standard for protein reagents, are undesirable for this task To begin, we needed to devise an appropriate selection because of the number of animals, amount of target, time, and protocol and library creation format. Typically, in vitro effort required to generate each reagent. Here, we developed selections require multiple rounds of modest sequential a unified approach to solve this problem by integrating four enrichment, followed by small-scale sequencing of functional distinct technologies: 1) a combinatorial protein library based clones (Figure 1A). Indeed, the need to generate a target- on the 10th fibronectin type III domain of human fibronectin specific library at each round provides a significant limitation (10Fn3),[3] 2) protein library display by mRNA display,[4] towards parallelizing and accelerating selections. In contrast, 3) selection by continuous-flow magnetic separation for identification of ligands after a single round of CFMS (CFMS),[5] and 4) sequence analysis by high throughput mRNA display (Figure 1A,B), only a single naive library pool sequencing (HTS).[6] Next generation sequencing has revolu- must be synthesized for any number of targets, drastically tionized many fields of biology, and is increasingly being used decreasing the effort needed for ligand discovery.
    [Show full text]
  • Expanding the Boundaries of Biotherapeutics with Bispecific
    BioDrugs https://doi.org/10.1007/s40259-018-0299-9 REVIEW ARTICLE Expanding the Boundaries of Biotherapeutics with Bispecifc Antibodies Bushra Husain1 · Diego Ellerman1 © The Author(s) 2018 Abstract Bispecifc antibodies have moved from being an academic curiosity with therapeutic promise to reality, with two molecules being currently commercialized (Hemlibra­ ® and Blincyto­ ®) and many more in clinical trials. The success of bispecifc antibodies is mainly due to the continuously growing number of mechanisms of actions (MOA) they enable that are not accessible to monoclonal antibodies. One of the earliest MOA of bispecifc antibodies and currently the one with the largest number of clinical trials is the redirecting of the cytotoxic activity of T-cells for oncology applications, now extending its use in infective diseases. The use of bispecifc antibodies for crossing the blood–brain barrier is another important application because of its potential to advance the therapeutic options for neurological diseases. Another noteworthy application due to its growing trend is enabling a more tissue-specifc delivery or activity of antibodies. The diferent molecular solutions to the initial hurdles that limited the development of bispecifc antibodies have led to the current diverse set of bispecifc or multispecifc antibody formats that can be grouped into three main categories: IgG-like formats, antibody fragment-based formats, or appended IgG formats. The expanded applications of bispecifc antibodies come at the price of additional chal- lenges for clinical development. The rising complexity in their structure may increase the risk of immunogenicity and the multiple antigen specifcity complicates the selection of relevant species for safety assessment.
    [Show full text]
  • Suderman Et Al. 2017
    Protein Expression and Purification 134 (2017) 114e124 Contents lists available at ScienceDirect Protein Expression and Purification journal homepage: www.elsevier.com/locate/yprep Development of polyol-responsive antibody mimetics for single-step protein purification * Richard J. Suderman a, , Daren A. Rice a, Shane D. Gibson a, Eric J. Strick a, David M. Chao a, b a Nectagen, Inc., 2002 W. 39th Ave, Kansas City, KS 66103, USA b Stowers Institute for Medical Research, BioMed Valley Discoveries, Inc., USA article info abstract Article history: The purification of functional proteins is a critical pre-requisite for many experimental assays. Immu- Received 24 March 2017 noaffinity chromatography, one of the fastest and most efficient purification procedures available, is often Received in revised form limited by elution conditions that disrupt structure and destroy enzymatic activity. To address this 13 April 2017 limitation, we developed polyol-responsive antibody mimetics, termed nanoCLAMPs, based on a 16 kDa Accepted 15 April 2017 carbohydrate binding module domain from Clostridium perfringens hyaluronidase. nanoCLAMPs bind Available online 17 April 2017 targets with nanomolar affinity and high selectivity yet release their targets when exposed to a neutral polyol-containing buffer, a composition others have shown to preserve quaternary structure and enzy- Keywords: Affinity purification matic activity. We screened a phage display library for nanoCLAMPs recognizing several target proteins, fi fi Antibody mimetics produced af nity resins with the resulting nanoCLAMPs, and successfully puri ed functional target nanoCLAMPs proteins by single-step affinity chromatography and polyol elution. To our knowledge, nanoCLAMPs Immunoaffinity constitute the first antibody mimetics demonstrated to be polyol-responsive.
    [Show full text]
  • Type of the Paper (Article, Review, Communication
    Review Volume 11, Issue 3, 2021, 10679 - 10689 https://doi.org/10.33263/BRIAC113.1067910689 Selective Preference of Antibody Mimetics over Antibody, as Binding Molecules, for Diagnostic and Therapeutic Applications in Cancer Therapy Pankaj Garg 1,* 1 Department of Chemistry, GLA University, Mathura, 281406, India * Correspondence: [email protected]; Scopus Author ID 571962558738 Received: 5.10.2020; Revised: 3.11.2020; Accepted: 4.11.2020; Published: 7.11.2020 Abstract: Despite wider use of monoclonal and polyclonal antibodies as therapeutic and diagnostic detection agents for different types of cancers, their limitations for biomedical applications have forced scientists to design alternate next-generation molecular binding reagents, the so-called antibody mimetics. The ultimate aim to produce antibody mimetics is to out-perform the intrinsic limitations of antibodies related to their binding affinities, tumor penetration, temperature, and pH stability. The current review highlights the advanced characteristics and constructional modification of alternate antibody mimetics, compared to animal source generated antibodies and their improved applications in bioanalytical chemistry; especially in cancer treatment as a diagnostic and therapeutic tool. Keywords:Antibody mimetic; Monoclonal antibodies (MoAbs); Protein scaffold engineering; Molecular Imaging; cancer therapy. © 2020 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). 1. Introduction Antibodies, especially monoclonal antibodies, on account of their high stability and specific affinity, have been identified as effective tools both for therapeutic and diagnostic applications, especially in cancer therapy. Antibodies are Y-shaped glycoproteins produced by the immune system to counteract the effect of any foreign substance or antigen in the body.
    [Show full text]
  • Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors
    Author Manuscript Published OnlineFirst on September 23, 2019; DOI: 10.1158/1078-0432.CCR-19-1479 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Title: Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors Authors: Ashwini Balakrishnan1 ‡, Anusha Rajan1 ‡, Alexander I. Salter1,2, Paula L Kosasih1, Qian Wu1, Jenna Voutsinas1, Michael C. Jensen2,3, Andreas Plückthun4, Stanley R. Riddell1,2 Authors Affiliations: 1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 2University of Washington, Seattle, Washington; 3Seattle Children’s Research Institute, Seattle, Washington. 4Department of Biochemistry, University of Zurich, Winterthurerstr. 190, 8057 Zurich, Switzerland. ‡ -These authors contributed equally to this work Authors’ Contributions Conception and design: A. Balakrishnan, A. Rajan, S.R. Riddell Development of methodology: A. Balakrishnan, A. Rajan, S.R. Riddell Acquisition of data (Performed experiments or provided reagents or plasmids etc): A. Balakrishnan, A. Rajan, A.I. Salter, P. L.Kosasih, M. C. Jensen, A. Plückthun, S.R. Riddell Analysis and interpretation of data: A. Balakrishnan, A. Rajan, S.R. Riddell Statistical Analysis: Q. Wu, J. Voutsinas Writing of the manuscript: A. Balakrishnan, A. Rajan, Alexander I. Salter, A. Plückthun, S.R. Riddell Study supervision: S.R. Riddell Running Title (60 characters, max 60 characters): Multispecific CAR design with ankyrin repeat binding domains Abbreviations list: scFv (single-chain variable fragment), DARPin (Designed Ankyrin Repeat proteins), CAR (chimeric antigen receptor), EGFR (epidermal growth factor receptor), EpCAM (Epithelial cell adhesion molecule), HER2 (human epidermal growth factor receptor 2), AICD (activation-induced cell death), tCD19 (truncated CD19), PBMC (Peripheral blood mononuclear cells), kDa (kilodalton), G4S ((Glycine)4-Serine), IFN-γ (Interferon gamma), IL2 (interleukin 2), MHC (major histocompatibility complex), nM (nanomolar) Corresponding author: Stanley R.
    [Show full text]
  • Affimer - Potential Best-In-Class Antibody Mimetic Pharma & Biotech
    Avacta Group Initiation of coverage Affimer - potential best-in-class antibody mimetic Pharma & biotech 13 June 2019 Avacta is developing its Affimer technology for use in therapeutic and diagnostic/reagent applications. The potential of the Affimer technology Price 30.5p lies in its formatting capabilities, particularly in the creation of bispecific Market cap £35m and TMAC Affimer drug conjugates. Its lead therapeutic asset (AVA004) is £:$ 1.30, £:€ 1.17, $:€ 0.89 a programmed death-ligand 1 (PD-L1)-targeting Affimer for which the Net cash (£m) at end January 2019 11.79 company expects to submit an investigational new drug (IND) application Shares in issue 116.2m in Q420. AVA004 will serve as the first clinical validation of the Affimer technology and will form the base of the clinical development of a PD- Free float 78.9% L1/LAG-3 bispecific (AVA021) and the first TMAC Affimer drug conjugate Code AVCT (AVA004/100). We value Avacta at £51m or 44p/share. Primary exchange AIM Secondary exchange N/A Revenue PBT* EPS* DPS P/E Yield Year end (£m) (£m) (p) (p) (x) (%) Share price performance 12/17 2.7 (7.9) (9.8) 0.0 N/A N/A 12/18 2.8 (10.4) (13.5) 0.0 N/A N/A 12/19e 3.2 (12.3) (9.0) 0.0 N/A N/A 12/20e 5.2 (12.4) (9.0) 0.0 N/A N/A Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. Formatting capabilities point to future potential Avacta is progressing its therapeutic Affimers towards the clinic with its PD-L1 (AVA004) and PD-L1/lymphocyte-activation gene 3 (LAG-3) (AVA021) product % 1m 3m 12m candidates expected to start oncology clinical trials in 2021 and 2022 respectively.
    [Show full text]
  • Protein Engineering Antibodies
    W I S S E N T E C H N I K L E I D E N S C H A F T 1 Protein Engineering Antibodies u www.tugraz.at MOL.921 Molecular Biotechnology II MOL.921 Molecular Biotechnology II 2 Antibody Engineering Target: Specific Affinity Variable region (Fv fragment) General structure of IgG antibodies IgG antibodies consist of two identical light and two identical heavy chains. These four chains are arranged in parallel and linked with different disulfide bonds to form a molecule. The antigen binding regions (VH = variable region of the heavy chain; VL = variable region of the light chain) are located Light chain at the N-terminus of each protein chain. In Constant (L) this region the antibodies can vary region tremendously. “Framework regions” (FR1- FR4) are distinguished from “complementary Heavy chain determining regions” (CDR1-CDR4). This part (L) of the antibody is named Fv-region. CL and Murine IgG OH are domains in the constant region of heavy and light chains. The region marked with “H” is the co-called “Hinge” region. MOL.921 Molecular Biotechnology II 3 IgG antibodies consist of 2 heavy (H) and 2 light (L) chains where the L chain can consist of either a or a chain. Each component chain contains one NH2- terminal variable (V) IgSF domain and 1 or more COOH-terminal constant (C) IgSF domains, each of which consists of 2 sandwiched b-pleated sheets pinned together by a disulfide bridge between 2 conserved cysteine residues. Papain digests IgG into 2 Fab fragments, each of which can bind antigen, and a single Fc fragment.
    [Show full text]